

Principal Investigator: *[Full name and degree(s)]*
Barbara Tavazzi, PhD

BIOGRAPHICAL SKETCH

Complete for each professional associated with the project

Name: *[Last, First, Middle Initial(s), Degree(s)]*
Gasperini Claudio, MD, PhD

Position/Title:
Consultant Neurologist

Education

[Begin with baccalaureate or other professional education and include postdoctoral training]

Institution and Location	Degree	Year Conferred	Field of Study
University of Rome "Sapienza"	MD	1989	Research Thesis on the following topic "Prognostic factors of ischemic stroke during acute phase"
University of Rome "Sapienza"	Neurologist	1993	Research Thesis on the following topic "Controlled study of potential risk factors in the occurrence of exacerbations in patients with Multiple Sclerosis"

Principal Investigator: [Full name and degree(s)]
Barbara Tavazzi, PhD

University of Rome "Sapienza"	PhD	1989	Clinical and Experimental Neuroscienze.
-------------------------------	-----	------	---

Research and Professional Experience

[List in chronological order, previous employment, experience and honors]

Positions and Honors

- 1989-1993** Resident in Neurology at University of Rome "Sapienza", Policlinico Umberto Hospital
- 1991-2002** – Teacher of Rehabilitative Neurology in the Therapy of Rehabilitation School of Carlo Forlanini Hospital in Rome
- 1993** - Study residence of one year in "The NMR research group of Multiple Sclerosis - Institute of Neurology - National Hospital of London, directed by Prof. Ian McDonald.
- 1996-1997** - Member of a research group of the European Community with regards to multicentric trials on the optimisation of the MRI usage in Multiple Sclerosis (MAGNIMS).
- 1996 to 1998** - Consultant Neurologist in Multiple Sclerosis Center of S. Camillo Hospital in Rome, Lancisi Division.
- 1998 to date** - Member of a Europe-United States Task Force on the MRI usage in Multiple Sclerosis.
- 1999-1999**- Coordinator of the following research project sponsored by "Multiple Sclerosis Italian Association (AISM) ": Effect of treatment with Interferon Beta on brain atrophy in patients with RRMS
- 2000 -2002** Member of the Coordinator Scientific Committee of an Italian Multicentric Trial on the efficacy of a treatment association of Interferon Beta plus Methylprednisolone vs Interferon Beta alone in patients affected by Secondary Progressive Multiple Sclerosis-
- 2001** - Coordinator in the following research project sponsored by "Multiple Sclerosis Italian Association (AISM) "Relationship between MRI measures and immunological markers in MS
- 1999 to date:** 1[^] Level Medical Manager as Consultant Neurologist at S. Camillo Hospital in Rome, Lancisi Division
- 1999 to date:** Principal investigator in several Phase II and III clinical trials on Multiple Sclerosis
- 2012 to date-** Member of the Steering Committee of MAGNIMS group.

Honors

- 1992** - Winner of a fellowship of the "Cenci Bolognetti" Foundation due to a project on the role of Heat shock proteins in Multiple Sclerosis.
- 1993.** Winner of a fellowship of the "Multiple Sclerosis Italian Association (AISM)" due to a project on the employment of new MRI quantitative techniques RMN in MS.

Principal Investigator: [Full name and degree(s)]
Barbara Tavazzi, PhD

Publications

For each investigator, provide complete bibliographic citations for selected **publications related to the topic of this application**. DO NOT exceed one page for each individual.

1. Thyroid autoimmunity and dysfunction in multiple sclerosis patients during long-term treatment with interferon beta or glatiramer acetate: an Italian multicenter study. Frisullo G, Calabrese M, Tortorella C, Paolicelli D, Ragonese P, Annovazzi P, Radaelli M, Malucchi S, Gallo A, Tomassini V, Nociti V, D'Onghia M, Lo Re V, Rodegher M, Solaro C, **Gasparini C**. *Mult Scler*. 2014 Aug;20(9):1265-8. Epub 2014 Feb 10.
2. From high- to low-frequency administered interferon-beta for multiple sclerosis: a multicenter study. Prosperini L, Mancinelli CR, Pozzilli C, Grasso MG, Clemenzi A, Collorone S, Pontecorvo S, Francia A, Villani V, Koudriavtseva T, Buttari F, Centonze D, Di Battista G, Frisullo G, Galgani S, **Gasparini C**. *Eur Neurol*. 2014;71(5-6):233-41. doi: 10.1159/000356786. Epub 2014 Jan 25.
3. Advances in the treatment of relapsing-remitting multiple sclerosis - critical appraisal of fingolimod. **Gasparini C**, Ruggieri S, Mancinelli CR, Pozzilli C. *Ther Clin Risk Manag*. 2013;9:73-85. doi: 10.2147/TCRM.S17426. Epub 2013 Mar 3.
4. Development of oral agent in the treatment of multiple sclerosis: how the first available oral therapy, fingolimod will change therapeutic paradigm approach. **Gasparini C**, Ruggieri S. *Drug Des Devel Ther*. 2012;6:175-86. doi: 10.2147/DDDT.S8927. Epub 2012 Jul 19. Review.
5. Emerging oral drugs for relapsing-remitting multiple sclerosis. **Gasparini C**, Ruggieri S. *Expert Opin Emerg Drugs*. 2011 Dec;16(4):697-712. doi: 10.1517/14728214.2011.642861. Epub 2011 Dec 7. Review.
6. Efficacy and safety of subcutaneous interferon β -1a in relapsing-remitting multiple sclerosis: further outcomes from the IMPROVE study. De Stefano N, Sormani MP, Stubinski B, Blevins G, Drulovic JS, Issard D, Shotekov P, **Gasparini C**. *J Neurol Sci*. 2012 Jan 15;312(1-2):97-101. doi: 10.1016/j.jns.2011.08.013. Epub 2011 Aug 31.
7. Escalation to natalizumab or switching among immunomodulators in relapsing multiple sclerosis. Prosperini L, Gianni C, Leonardi L, De Giglio L, Borriello G, Galgani S, Pozzilli C, **Gasparini C**. *Mult Scler*. 2012 Jan;18(1):64-71. doi: 10.1177/1352458511417481. Epub 2011 Aug 9.
8. Quality of life, depression and fatigue in mildly disabled patients with relapsing-remitting multiple sclerosis receiving subcutaneous interferon beta-1a: 3-year results from the COGIMUS (COGNitive Impairment in MULTiple Sclerosis) study. Patti F, Amato MP, Trojano M, Bastianello S, Tola MR, Picconi O, Cilia S, Cottone S, Centonze D, **Gasparini C**; COGIMUS Study Group. *Mult Scler*. 2011 Aug;17(8):991-1001. doi: 10.1177/1352458511401943. Epub 2011 Apr 18.
9. Emerging oral treatments in multiple sclerosis - clinical utility of cladribine tablets. **Gasparini C**, Ruggieri S, Pozzilli C. *Ther Clin Risk Manag*. 2010 Sep 7;6:391-9.
10. Rapid benefits of a new formulation of subcutaneous interferon beta-1a in relapsing-remitting multiple sclerosis. De Stefano N, Curtin F, Stubinski B, Blevins G, Drulovic J, Issard D, Shotekov P, **Gasparini C**; IMPROVE Study Investigators. *Mult Scler*. 2010 Jul;16(7):888-92. doi: 10.1177/1352458510362442. Epub 2010 Mar 3.
11. Emerging oral drugs for multiple sclerosis. **Gasparini C**, Cefaro LA, Borriello G, Tosto G, Prosperini L, Pozzilli C. *Expert Opin Emerg Drugs*. 2008 Sep;13(3):465-77. doi: 10.1517/14728214.13.3.465 . Review.
12. MRI brain volume changes in relapsing-remitting multiple sclerosis patients treated with interferon beta-1a. **Gasparini C**, Paolillo A, Giugni E, Galgani S, Bagnato F, Mainero C, Onesti E, Bastianello S, Pozzilli C. *Mult Scler*. 2002 Apr;8(2):119-23.
13. Monthly corticosteroids decrease neutralizing antibodies to IFNbeta1 b: a randomized trial in multiple sclerosis. Pozzilli C, Antonini G, Bagnato F, Mainero C, Tomassini V, Onesti E, Fantozzi R, Galgani S, Pasqualetti P, Millefiorini E, Spadaro M, Dahlke F, **Gasparini C**. *J Neurol*. 2002 Jan;249(1):50-6.